Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Search Results

Now showing 1 - 10 of 15
  • Item
    The Association of Upper Extremity Deep Vein Thrombosis and Homozygosity for the MTHFR 1298A-C Mutation in a Young Women with Membranoproliferative Glomerulonephritis
    (2014) Yildiz, Ismail; Torun, Dilek; Ozelsancak, Ruya; Ozkan, Ugur; Canpolat, Tuba; 0000-0002-6267-3695; 0000-0002-0788-8319; AAD-9111-2021; AAD-5716-2021; AAK-8107-2021
    Nephrotic syndrome increases the tendency to thromboembolic complications in both adults and children. Changes in the plasma concentrations of many proteins concerned with regulation of clotting and fibrinolytic systems, hyperviscosity, dehydration, corticosteroid and diuretic therapy may also contribute to thromboembolism. In addition, some of the genetic disorders also increase tendency to thromboembolic events. One of these disorders is methylene tetrahydrofolate reductase (MTHFR) A1298C mutation, which may cause hyperhomocysteinemia and thrombotic events when the folate level is low. A 26-year-old female was admitted to hospital with upper extremity deep vein thrombosis and nephrotic range proteinuria. On her renal biopsy, membranoproliferative glomerulonephritis (MPGN) was found. The other causes of thrombosis were excluded and homozygosity for the MTHFR A1298C mutation was determined. The levels of homocysteine and folic acid were normal. We report a first case of MPGN together with homozygosity for MTHFR 1298C mutation in adult nephrotic syndrome, complicated with unusual upper extremity venous thrombosis.
  • Item
    Termination of Hemodialysis Treatment on the 5th Month of Mycophenolate Mofetil in Type 4 Lupus Nephritis with Serious Renal Failure: A Case Report
    (2015) Torun, Dilek; Micozkadioglu, Hasan; Ozelsancak, Ruya; Yildiz, Ismail; 0000-0002-6267-3695; 0000-0001-5142-5672; 0000-0002-0788-8319; AAD-9111-2021; AAE-7608-2021; AAD-5716-2021
    Systemic lupus erythematosus (SLE) is a chronic, occasionally life-threatening, multisystem disorder, and renal involvement is one of the most common and most serious complications of SLE. Among the various histological types of lupus nephritis, diffuse proliferative nephritis carries the worst prognosis. A 28-year-old woman was admitted to Baskent University Adana Hospital with the complaints of dyspnea, chest pain, and fatigue. The patient had active lupus manifestations including generalized pleural and pericardial effusion, hypoalbuminemia, anemia, leucopenia, hypocomplementemia, markedly elevated ANA, acute kidney injury, and uncontrolled hypertension. Renal biopsy had been performed at another institute and shown type 4 lupus nephritis. She had been managed with methylprednisolone and cyclophosphamide (CYP) for 6 months. We started immunosuppressive therapy with intravenous methylprednisolone (1 gr/day) for 3 days as an induction therapy. The treatment was continued with oral methylprednisolone 0.5 mg/kg/day and mycophenolate mofetil (MMF) 1 gr/day. Hemodialysis (HD) therapy was initiated because of progressive renal failure and hypervolemia during the clinical course. Despite the improvement in her general condition, the patient underwent HD treatment three times a week for 5 months. On the fifth month of MMF therapy the renal function and diuresis were progressively improved and HD treatment was terminated. Management with MMF may be effective for remission of lupus nephritis in patients who are nonresponders to initial CYC therapy.
  • Item
    The Effect of Serum Mannose-Binding Lectin Levels on Dialysis-Related Peritonitis and Catheter-Related Bacteremia
    (2015) Erken, Ertugrul; Torun, Dilek; Sezgin, Nurzen; Micozkadioglu, Hasan; Zumrutdal, Aysegul; Ozelsancak, Ruya; Yildiz, Ismail; 0000-0002-6267-3695; 0000-0002-0788-8319; 0000-0001-5142-5672; 0000-0002-7054-1203; AAD-9111-2021; AAD-5716-2021; AAE-7608-2021; P-4517-2015
    OBJECTIVE: Mannose-binding lectin (MBL) takes part in innate immunity through opsonisation and complement activation. Deficiency of MBL is associated with some infections and autoimmune disorders. This study focused on functional MBL deficiency and its effects on dialysis-related peritonitis and catheter-related bacteremia in patients with end stage renal disease. MATERIAL and METHODS: The study included 51 patients on chronic peritoneal dialysis (PD) program and 31 under maintenance hemodialysis (HD) who had tunneled/cuffed hemodialysis catheters (total 82). Serum MBL level measurements were performed by ELISA technique. RESULTS: The mean value for serum MBL in patient groups of PD, HD, and healthy controls were 2536.5 ng/ml, 2088.7 ng/ml, 1924 ng/ml respectively. Difference of MBL level was not significant among groups. Serum MBL value was negatively correlated to the number of peritonitis episodes in PD group (p=0.019). Deficiency of MBL was not associated with high incidence of peritonitis. Surveillance of catheter associated blood stream infection for tunneled/cuffed hemodialysis catheters was 2.07 episodes/1000 catheter days. An association with MBL deficiency and incidence of catheter-related bacteremia was not observed. CONCLUSION: Serum MBL value was negatively correlated to the number of peritonitis episodes but an expected association of MBL deficiency with high incidence of dialysis-related peritonitis and catheter-related bacteremia was not found. New studies with greater sample size might probably indicate the potential effect of MBL deficiency on dialysis-related peritonitis.
  • Item
    Fibromyalgia Syndrome in Turkish Hemodialysis Patients
    (2016) Leblebici, Berrin; Ozelsancak, Ruya; Yilmaz, Emine Ece; Doruk, Pinar; https://orcid.org/0000-0002-6241-268X; https://orcid.org/0000-0002-0788-8319; https://orcid.org/0000-0002-8602-6038; https://orcid.org/0000-0002-3528-3712; 26198740; AAM-3220-2021; AAD-5716-2021; AAA-8043-2021
    The aim of our study was to evaluate the frequency of fibromyalgia syndrome (FMS) in hemodialysis (HD) patients and to assess whether this syndrome is associated with gender, age, duration of HD, or various laboratory parameters. This study was composed of 221 chronic HD patients (99 females and 122 males), and we recorded each participant's age, gender, causes of kidney failure, HD duration, education level, and symptoms related to FMS, which was diagnosed according to the 2010 American College of Rheumatology criteria. We documented the laboratory parameters for all patients. In addition, patients with FMS filled out the Fibromyalgia Impact Questionnaire. Twenty-two patients met the diagnostic criteria for FMS (9%), and there were no statistically significant differences related to age, gender, or HD duration between FMS and non-FMS groups (P>0.05). In addition, the education levels were lower in patients diagnosed with FMS (P<0.05), and there were statistically significant differences related to sleep disturbance, fatigue, and cognitive symptoms between the two groups (P<0.05) as well. However, their laboratory parameters were similar (P>0.05). There was a higher prevalence of FMS in HD patients than in the general population. Sleep disturbances, fatigue, education level, and cognitive symptoms were associated with FMS, but there was no correlation between the laboratory parameters and this condition.
  • Item
    The Effect of Hemodialysis on Balance Measurements and Risk of Fall
    (2016) Erken, Ertugrul; Ozelsancak, Ruya; Sahin, Safak; Yilmaz, Emine Ece; Torun, Dilek; Leblebici, Berrin; Kuyucu, Yunus Emre; Sezer, Siren; https://orcid.org/0000-0002-0788-8319; https://orcid.org/0000-0002-6267-3695; 27497737; AAD-5716-2021; AAD-9111-2021
    Patients with end-stage renal disease (ESRD) have increased risk of falls and fall-related complications. Other than aging and factors related to chronic kidney disease, treatment of hemodialysis may also contribute to this increased risk. The aim of this study was to demonstrate the impairment of balance after a session of hemodialysis with a quantitative assessment and reveal an increased fall risk that would possibly be related to treatment of hemodialysis for patients on maintenance hemodialysis. Fifty-six patients with ESRD on chronic hemodialysis program and 53 healthy individuals were involved in this study. Fall Index percentages were calculated, and fall risk categories were determined for all patients and healthy controls using Tetrax posturography device (Sunlight Medical Ltd Israel). The patient group was evaluated twice for balance, before and after a routine session of hemodialysis. Fall Index scores of healthy controls were lower than that of ESRD patients (p = 0.001). In the patient group, we found the mean Fall Index to be significantly higher at the post-dialysis assessment compared to the pre-dialysis assessment (p = 0.003). The number of patients with high risk of falling also increased at the post-dialysis assessment yet the difference did not reach significance. Fall Index was correlated with the increase in age only at the pre-dialysis balance measurement (p = 0.038). Patients with better dialysis adequacy had significantly lower Fall Index scores than the others at the pre-dialysis balance measurement (p = 0.004). The difference was not significant at the post-dialysis measurement. In the current study, we evaluated the balance of ESRD patients before and after a routine session of hemodialysis treatment. This is the first study to investigate the effect of hemodialysis on balance, using an electronic posturographic balance system. We found the Fall Index score to be significantly higher after hemodialysis, indicating a negative effect of hemodialysis on postural stability. As expected, our data showed an increased Fall Index score correlated with the increase in age both in ESRD patients and in healthy controls. However, the correlation with age was not observed for the patient group at the post-dialysis balance measurement. We might conceive that young patients with ESRD are also prone to fall risk after a session of hemodialysis. Methods that provide quantitative assessment for fall risk could be rather beneficial for high-risk populations such as patients on maintenance hemodialysis.
  • Item
    Risk Factors for Urinary Tract Infection After Kidney Transplant: A Retrospective Analysis
    (2020) Tekkarimaz, Nihan; Ozelsancak, Ruya; Micozkadioglu, Hasan; Caliskan, Kenan; Demiroglu, Yusuf Ziya; Arslan, Ayse Hande; H, Mehmet; 0000-0001-5142-5672; 0000-0001-7631-7395; 0000-0002-0788-8319; 0000-0002-8767-5021; 0000-0002-3462-7632; 31424358; AAE-7608-2021; AAD-9088-2021; AAD-5716-2021; AAJ-7201-2021; AAJ-8097-2021
    Objectives: Urinary tract infections are the most common type of infections in kidney transplant recipients. They are also important factors for increased morbidity and mortality. The aims of this study were to evaluate the number of urinary tract infections, to identify possible donor/receiver-based risk factors, and to evaluate the impact of these infections on graft function. Materials and Methods: Medical records of patients who had undergone kidney transplant between 2010 and 2017 were retrospectively analyzed. Results: Our study included 145 patients (49 women [33.8%] and 96 men [66.2%]), with mean age of 35.2 +/- 12.4 years. There were 105 episodes of urinary tract infections in 55 of 145 patients (37.9%) during the first year after transplant. Female sex (P = .001), glomerulonephritis as primary kidney disease (P = .04), pretransplant diabetes (P = .05), and presence of ureteral stent (P = .03) were significant risk factors for the development of urinary tract infections. The most frequent pathogens identified were Escherichia coli and Klebsiella pneumoniae. Mean glomerular filtration rate at 12 months was significantly lower in patients with urinary tract infection than in patients without infection (80 +/- 25 vs 68 +/- 28 mL/min; P = .006). Conclusions: In kidney transplant recipients, urinary tract infections are common complications and have negative outcomes on graft function. These infections remain an important disease that requires frequent investigations and new ways of approach for prevention.
  • Item
    Factors Associated with Fibromyalgia Syndrome in Peritoneal Dialysis Patients
    (2019) Ozelsancak, Ruya; Analan, Pinar Doruk; Leblebici, Berrin; 0000-0002-3528-3712; 0000-0002-0788-8319; 30787502; AAA-8043-2021; AAD-5716-2021
    Purpose: We evaluated the prevalence of fibromyalgia syndrome (FMS) in peritoneal dialysis (PD) patients and whether this syndrome is associated with gender, age, duration of PD, or other laboratory parameters. Methods: A total of 60 chronic PD patients (26 women, 34 men) and 60 healthy controls (30 women, 30 men) were included. We recorded each participant's age, gender, cause of kidney failure, PD duration, laboratory parameters, education level, and symptoms related to FMS, diagnosed according to the 2010 American College of Rheumatology criteria. Results: Eleven patients (18%) in the PD group and nine (15%) in the control group met the diagnostic criteria for FMS. There were no statistically significant differences in age; gender; education level; PD duration; laboratory parameters; or sleepdisturbance, fatigue, or cognitive symptoms between the FMS and non-FMS groups among the PD patients. We next compared control and PD patients with FMS. Both groups were of a similar age and gender and had similar sleep disturbance and cognitive symptoms, but more patients had fatigue in the control group. Conclusions: The prevalence of FMS among PD patients was similar to that in the general population, and FMS was not associated with gender, age, duration of PD, or other laboratory parameters.
  • Item
    Balance and fall risk in peritoneal dialysis patients
    (2019) Analan, Pinar Doruk; Ozelsancak, Ruya; 0000-0002-3528-3712; 0000-0002-0788-8319; 30248027; AAA-8043-2021; AAD-5716-2021
    BACKGROUND: Vestibular, neurological and musculoskeletal functions are affected in patients with renal failure. These problems can in turn affect the balance system in peritoneal dialysis (PD) patients. Previously, postural balance changes were shown in hemodialysis patients. This is the first study that evaluates whether there are similar changes in patients with PD. OBJECTIVE: This study aimed to compare balance and fall risk between patients undergoing PD treatment and healthy subjects, and aimed to determine the correlation between biochemical parameters and fall risk and balance assessments in PD patients. METHODS: This controlled study included 58 patients receiving PD treatment (PD Group) and 75 healthy subjects (Control Group). The Berg Balance Scale (BBS) and Tetrax (R) Interactive Balance System were used for the comparison of balance between groups. For patients in the PD Group, duration of PD, blood pressure, Kt/V-urea (actual mass of urea removed via peritoneal dialysis), and serum biochemical parameters were recorded and correlation analysis was performed between these parameters and balance measurements. RESULTS: There were no statistically significant differences between groups in terms of demographics or BBS scores (p > 0.05). The fall risk of patients in the PD Group was significantly higher than those in the Control Group (p < 0.0001) according to Tetrax measurements. Female gender, older age, higher BMI, and higher blood glucose levels were negatively correlated with balance parameters of PD patients (r > 0.3). There was no statistically significant correlation between duration of PD, blood pressure, and Kt/V-urea with balance parameters or fall risk. CONCLUSIONS: Balance was impaired in patients undergoing PD in comparison to healthy subjects. Fall risk may be evaluated using the Tetrax (R) instead of BBS for this population. Serum glucose level, BMI and age appear to affect balance and fall risk. Therefore, optimization of body weight and normalization of serum glucose levels are important factors for improving balance. The duration of PD, blood pressure, and Kt/V-urea do not affect balance system.
  • Item
    Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait list
    (2019) Torun, Dilek; Soydas, Baris; Tekkarismaz, Nihan; Ozelsancak, Ruya; Micozkadioglu, Hasan; Haberal, Mehmet; 30762283
    Introduction Hepatitis C virus (HCV) infection is associated with increased mortality and morbidity in kidney transplant patients. The ability to establish a sustained viral response before renal transplant is important for these patients. Direct-acting antiviral agents can increase the sustained viral response in most patients with HCV infection. In this case series, we aimed to determine the efficacy and safety of a combined therapy of ombitasvir, paritaprevir, ritonavir, and dasabuvir with or without ribavirin in patients with HCV genotype 1 infection without cirrhosis and on hemodialysis who were awaiting deceased-donor kidney transplant. Methods Our study included eight male and two female HCV ribonucleic acid (RNA)-positive hemodialysis patients (mean age 50.7 +/- 15 years, mean hemodialysis duration 14 +/- 5.5 years, mean HCV duration 18 +/- 3.7 years). Findings Three patients with genotype 1a received oral therapy with 12.5 mg ombitasvir, 150 mg paritaprevir, 7 5 mg ritonavir, and 250 mg dasabuvir plus 200 mg ribavirin for 12 weeks. Seven patients with genotype 1b received 12.5 mg ombitasvir, 150 mg paritaprevir, 75 mg ritonavir, and 250 mg dasabuvir without ribavirin treatment for 12 weeks. The sustained virologic response rate was 100% at 12 weeks after completion of antiviral treatment in both treatment groups. No serious adverse effects were observed in either treatment group. Five patients had constitutional symptoms such as nausea, anorexia, and fatigue. During the treatment period, hemoglobin, white cell blood count, thrombocyte, and ferritin levels were similar to pretreatment levels. Treatment did not affect weekly erythropoietin and monthly intravenous iron treatment doses. Discussion Direct-acting antiviral agents are safe and effective for generating a sustained viral response in HCV genotype 1-infected hemodialysis patients on kidney wait lists.
  • Item
    Heart Valve Disease Predict Mortality in Hemodialysis Patients: A Single Center Experience
    (2019) Ozelsancak, Ruya; Tekkarismaz, Nihan; Torun, Dilek; Micozkadioglu, Hasan; 0000-0002-0788-8319; 30421548
    Our aim is to investigate the clinical and laboratory findings affecting the mortality of the patients in 3 years follow-up who underwent hemodialysis at our center. In this retrospective, observational cohort study, 432 patients who underwent hemodialysis at our center for at least 5 months were included. The first recorded data and subsequent clinical findings of patients who died and survived were compared. Two hundred and ninety patients survived, 142 patients died. The mean age of the patients who died was higher (63.4 +/- 12.3 years, vs. 52 +/- 16.1 years, P = 0.0001), 60.5% of them had coronary artery disease (P = 0.0001), 93.7% of them had a heart valve disease. Duration of hemodialysis (survived 57 [21-260] months; died 44 [5-183] months, P = 0.000) was lower in patients who died. Serum potassium level before dialysis (5.1 +/- 0.6; 4.9 +/- 0.7 mEq/L, P = 0.030), parathyroid hormone (435 [4-3054]; 304 [1-3145] pg/mL, P = 0.0001), albumin (3.9 +/- 0.4; 3.8 +/- 0.4 mg/dL, P = 0.0001) and Kt/V (1.48 +/- 0.3; 1.40 +/- 0.3, P = 0.019) levels were lower, C-reactive protein (5[1-208]; 8.7[2-256] mg/L, P = 0.000) levels were higher in patients who died. Logistic regression analysis showed age (OR = 1.1), coronary artery disease (OR = 1.7) and more than one heart valve disease (OR = 2.4) are independent risk factors for mortality. Potassium level before dialysis (OR = 0.60), parathyroid hormone (OR = 0.99), and higher Kt/V (OR = 0.28) were found to be an advantage for survival. Age, coronary artery disease and especially pathology in more than one heart valve are risk factors for mortality. Heart valve problems might develop because of malnutrition and inflammation caused by the chronic renal failure.